Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 106
Filtrar
1.
Eur Arch Psychiatry Clin Neurosci ; 268(4): 349-357, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28766128

RESUMO

The present study was aimed at verifying whether the presence of generalized anxiety disorder (GAD) affects executive functions in children with attention-deficit hyperactivity disorder (ADHD). Two groups of children with ADHD were selected for the study according to the presence or absence of GAD. The first group of 28 children with ADHD with GAD (mean age: 9 ± 1.2; males/females: 24/4) was matched for gender, age, IQ, psychiatric comorbidity with a second group of 29 children with ADHD without GAD (mean age: 8.8 ± 0.7; males/females: 26/3). The two groups with ADHD were compared to 28 typically developing children (mean age: 8.3 ± 1.3; males/females: 23/5) on different measures involving processes especially important in inhibitory control such as rule maintenance, stimulus detection, action selection and action execution. Our results indicated that, differently from children with ADHD with GAD, only the group with ADHD without GAD showed a deficit in inhibitory control. Comorbid subgroups should be differentiated, especially, to develop specific and efficient therapeutic interventions in ADHD.


Assuntos
Transtornos de Ansiedade/complicações , Transtorno do Deficit de Atenção com Hiperatividade/complicações , Função Executiva/fisiologia , Adolescente , Transtornos de Ansiedade/epidemiologia , Transtorno do Deficit de Atenção com Hiperatividade/epidemiologia , Criança , Feminino , Humanos , Inibição Psicológica , Masculino , Testes Neuropsicológicos , Escalas de Graduação Psiquiátrica , Estatísticas não Paramétricas
2.
Br J Cancer ; 112(6): 1011-6, 2015 Mar 17.
Artigo em Inglês | MEDLINE | ID: mdl-25742483

RESUMO

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are associated with prolongation of the QTc interval on the electrocardiogram (ECG). The QTc-interval prolongation increases the risk of life-threatening arrhythmias. However, studies evaluating the effects of TKIs on QTc intervals are limited and only consist of small patient numbers. METHODS: In this multicentre trial in four centres in the Netherlands and Italy we screened all patients who were treated with any TKI. To evaluate the effects of TKIs on the QTc interval, we investigated ECGs before and during treatment with erlotinib, gefitinib, imatinib, lapatinib, pazopanib, sorafenib, sunitinib, or vemurafenib. RESULTS: A total of 363 patients were eligible for the analyses. At baseline measurement, QTc intervals were significantly longer in females than in males (QTcfemales=404 ms vs QTcmales=399 ms, P=0.027). A statistically significant increase was observed for the individual TKIs sunitinib, vemurafenib, sorafenib, imatinib, and erlotinib, after the start of treatment (median ΔQTc ranging from +7 to +24 ms, P<0.004). The CTCAE grade for QTc intervals significantly increased after start of treatment (P=0.0003). Especially patients who are treated with vemurafenib are at increased risk of developing a QTc of ⩾470 ms, a threshold associated with an increased risk for arrhythmias. CONCLUSIONS: These observations show that most TKIs significantly increase the QTc interval. Particularly in vemurafenib-treated patients, the incidence of patients at risk for arrhythmias is increased. Therefore, especially in case of combined risk factors, ECG monitoring in patients treated with TKIs is strongly recommended.


Assuntos
Síndrome de Jervell-Lange Nielsen/induzido quimicamente , Inibidores de Proteínas Quinases/efeitos adversos , Proteínas Tirosina Quinases/antagonistas & inibidores , Idoso , Arritmias Cardíacas/induzido quimicamente , Arritmias Cardíacas/epidemiologia , Eletrocardiografia/métodos , Feminino , Humanos , Incidência , Itália/epidemiologia , Síndrome de Jervell-Lange Nielsen/enzimologia , Síndrome de Jervell-Lange Nielsen/epidemiologia , Masculino , Pessoa de Meia-Idade , Países Baixos/epidemiologia , Estudos Retrospectivos , Risco
3.
G Chir ; 36(5): 205-8, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26712256

RESUMO

AIM: The aim of this study was to compare the short-term surgical outcomes of laparoscopically-assisted right hemicolectomy (LRH) and open right hemicolectomy (ORH) in elderly patients. Patients and methods-Results. Seventy-five patients underwent right hemicolectomy for cancer during the study period, with 41 patients aged ≥ 70 years old. Twenty-four patients underwent ORH and seventeen patients had a LRH (58% vs 42%).We found no differences between ORH and LRH in terms of mean operative time :89,5 minutes in open vs 80 minutes in laparoscopic group and return of bowel function (2,76 vs 2,54 days). Also the length of hospital stay did not differ significantly between the two groups (8,5 days in ORH vs 7 days in LRH - p 0,06). Postoperative morbidity was higher in ORH (25% vs 5%) though not statistically significant and the incidence of anastomotic leakage was similar between the two groups (8% vs 5%). CONCLUSION: Laparoscopic RH in an elderly population is feasible and safe. However, we found no evidence to suggest that it is better than open RH and think that the decision regarding the method of operation should reflect surgeon expertise, patient co-morbidities and the necessity to perform extended resections.


Assuntos
Colectomia , Neoplasias do Colo/cirurgia , Laparoscopia , Idoso , Fístula Anastomótica/epidemiologia , Colectomia/métodos , Colectomia/estatística & dados numéricos , Neoplasias do Colo/epidemiologia , Neoplasias do Colo/patologia , Estudos de Viabilidade , Feminino , Humanos , Incidência , Itália/epidemiologia , Laparoscopia/métodos , Laparoscopia/estatística & dados numéricos , Tempo de Internação/estatística & dados numéricos , Masculino , Estadiamento de Neoplasias , Duração da Cirurgia , Estudos Retrospectivos , Fatores de Risco , Resultado do Tratamento
4.
G Chir ; 36(5): 225-30, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26712261

RESUMO

Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy with an estimated worldwide incidence of 0.5-2 per million/year. Complete surgical removal of ACC represents the current treatment of choice for this tumor. A disease-free resection margin (R0) is an important predictor of long-term survival: surgery is demanding and must be performed by a highly experienced surgical team. We report the surgical strategy adopted in a patient with locally advanced ACC and virilization to obtain a R0 resection.


Assuntos
Neoplasias do Córtex Suprarrenal/cirurgia , Adrenalectomia , Carcinoma Adrenocortical/cirurgia , Nefrectomia , Neoplasias do Córtex Suprarrenal/complicações , Neoplasias do Córtex Suprarrenal/patologia , Carcinoma Adrenocortical/complicações , Carcinoma Adrenocortical/patologia , Idoso , Artéria Celíaca/cirurgia , Feminino , Humanos , Veias Mesentéricas/cirurgia , Invasividade Neoplásica , Estadiamento de Neoplasias , Pâncreas/cirurgia , Prognóstico , Artéria Esplênica/cirurgia , Veia Esplênica/cirurgia , Resultado do Tratamento , Ureter/cirurgia , Procedimentos Cirúrgicos Vasculares , Virilismo/etiologia
5.
J Endocrinol Invest ; 36(2): 92-6, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22398397

RESUMO

Glucocorticoid-induced osteoporosis (GIO) is the most frequent cause of secondary osteoporosis. GIO is linked to glucocorticoids (GC) daily assumption with maximum effect within first months of treatment and decreasing to basal levels as the therapy is discontinued. In Italy, primary prevention of GIO is suggested when GC therapy (prednisone >5 mg/day or equivalent) is taken for longer than 3 months. Lazio GISMO (Italian Group for Study and Diagnosis of Bone Metabolism Diseases) group organized the GC and Osteoporosis Epidemiology study (EGEO) to evaluate physician's approach in preventing GIO. The study involved 19 osteoporosis centers. Patients taking long-term GC therapy were recruited and information collected: medical history and anthropometric data, GC therapy, primary disease, physician's specialty, osteopororosis screening, and pharmacological intervention. The study included 1334 patients. Mean age was 63 ± 13 yr; 243 (18%) patients had a history of falls from standing position in the previous 12 months, 78 (35%) vertebral fractures, 91 (41%) fractures other than vertebral, 27 (12%) femoral fractures, and 27 (12%) multiple sites fractures. The molecules of GC more often prescribed were prednisone and 6-metil prednisolone. One thousand and forty patients (78%) were taking GC for more than 6 months. GC therapy was prescribed more frequently by rheumatologists (62%). Antiosteoporotic drugs for GIO prevention were prescribed in 431 patients (32%). Among the patients, only 27% (360) received calcium and vitamin D supplements, and 39% (319) treated by rheumatologists received anti-resorptive drugs. In conclusion, our data show that in Italy, as already described elsewhere, only a small subpopulation of GC-treated patients was supported by an anti-osteoporotic therapy, indicating the need to further stimulate awareness of both patients and specialists, prescribing GC therapy, to an appropriate and prompt GIO prevention.


Assuntos
Glucocorticoides/efeitos adversos , Osteoporose/induzido quimicamente , Osteoporose/prevenção & controle , Adulto , Idoso , Idoso de 80 Anos ou mais , Densidade Óssea/efeitos dos fármacos , Densidade Óssea/fisiologia , Estudos de Coortes , Feminino , Humanos , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Osteoporose/epidemiologia , Estudos Prospectivos , Adulto Jovem
6.
Radiol Med ; 117(8): 1294-308, 2012 Dec.
Artigo em Inglês, Italiano | MEDLINE | ID: mdl-22430684

RESUMO

PURPOSE: Assessing myocardial viability is crucial in decision making and prognostic restratification after acute myocardial infarction (MI). A number of noninvasive imaging modalities have been employed in viability identification, but contrast-enhanced magnetic resonance (MR) imaging has been shown to be extremely accurate because of its transmural resolution and precise definition of microvascular obstruction. Our purpose was to assess functional recovery after acute MI, with special focus on the role of infarct transmurality and microvascular obstruction. MATERIALS AND METHODS: Forty-six consecutive patients with first acute MI, reperfused by primary percutaneous transluminal coronary angioplasty (PTCA) (n=40) or fibrinolysis (n=6), underwent MR imaging within the first week to assess oedema, microvascular obstruction, function and viability and then again after 4-6 months to assess functional recovery and scar. RESULTS: At first MR examination, postcontrast images were analysed according to three patterns, based on a combination of first-pass and delayed-enhancement data: pattern 1 (normal first pass and late hyperenhancement <50% thickness) identified viable myocardium, whereas pattern 2 (late hyperenhancement >50% thickness, with or without first-pass perfusion defect) and pattern 3 (perfusion defect at first pass and late hypoenhancement) recognised nonviable myocardium, with 93% sensitivity, 75% specificity, 92% positive predictive value and 78% negative predictive value for identifying viable tissue. Furthermore, by dividing pattern 2 into two subpatterns, 2A and 2B, based on absence or presence of microvascular obstruction in >50% transmural infarcts, we were able to better identify the segments without recovery or that were nonviable with a 1.39 relative risk of failed recovery. CONCLUSIONS: After acute MI, not all infarcts with transmurality >50% can be considered nonviable; microvascular obstruction detected at first pass can help to better stratify these cases.


Assuntos
Meios de Contraste , Gadolínio DTPA , Imageamento por Ressonância Magnética , Infarto do Miocárdio/diagnóstico , Angioplastia Coronária com Balão , Humanos , Infarto do Miocárdio/fisiopatologia , Sensibilidade e Especificidade , Sobrevivência de Tecidos
7.
Comp Immunol Microbiol Infect Dis ; 83: 101769, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-35228159

RESUMO

Antibodies against Spotted Fever Group (SFG) Rickettsia and Coxiella burnetii, investigated through indirect antibody immunofluorescence tests, were detected in serum samples from 3.1% and 0% of 358 rural dogs, respectively, and in none of 32 wild foxes tested. SFG Rickettsia seropositive dogs were only detected in the Mountain Desert (8%) and the Steppe-Mediterranean (9%) regions. Exposure in the Mountain Desert, where no ticks and fleas were found on any dog, could correspond to a new SFG Rickettsia sp. recently described in soft ticks or to a related agent. Our survey confirms low endemicity in the country of C. burnetii, as observed in recent serosurveys in humans.


Assuntos
Coxiella burnetii , Doenças do Cão , Rickettsia , Rickettsiose do Grupo da Febre Maculosa , Animais , Chile/epidemiologia , Doenças do Cão/microbiologia , Cães , Raposas , Rickettsiose do Grupo da Febre Maculosa/epidemiologia , Rickettsiose do Grupo da Febre Maculosa/veterinária
8.
Isotopes Environ Health Stud ; 58(4-6): 316-326, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35968628

RESUMO

Darwin's fox is an opportunistic omnivorous predator native to Chile classified as endangered by the IUCN Red List. Habitat use by Darwin's foxes can be negatively affected by the presence of free-ranging dogs that range freely across native and non-native habitats and can be a source of fox mortality. The objective of this study was to analyze the isotopic similarity of Darwin's fox and sympatric free-ranging dogs in Chiloé Island to determine the impact of anthropogenic environmental alterations on wild predators. We use hair samples to characterise and compare their δ13C and δ15N values and to evaluate isotopic similarity and isotope niches overlap. A generalised linear model was used to associate the isotope value with landscape variables (forest cover and vegetation type) and distance to the nearest house. We found no significant differences in δ13C or δ15N values between foxes and dogs, and a marginally significant isotope niche overlap (59.4 %). None of the selected variables at landscape and site scale were related to isotope values. Although our study is not a probe of direct contact between foxes and free-ranging dogs, the high isotopic similarity highlights the risk of pathogen spillover from free-ranging dogs to Darwin's foxes.


Assuntos
Carbono , Cães , Animais , Isótopos de Nitrogênio , Chile
9.
Transplant Proc ; 41(3): 962-4, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19376399

RESUMO

OBJECTIVE: Arrhythmogenic right ventricular dysplasia (ARVD) is a myocardial disease of familiar, origin where the myocardium is replaced by fibrofatty tissue predominantly in the right ventricle. Herein we have presented the clinical courses of 4 patients with ARVD who underwent orthotopic heart transplantation. PATIENTS AND METHODS: Among 358 adult patients undergoing heart transplantation, 4 (1.1%) displayed ARVD. The main indication for transplantation was the progression to heart failure associated with arrhythmias. All 4 patients displayed rapid, severe courses leading to heart failure with left ventricular involvement and uncontrolled arrhythmias. RESULTS: In all cases the transplantation was performed using a bicaval technique with prophylactic tricuspid valve annuloplasty. One patient developed hyperacute rejection and infection, leading to death on the 7th day after surgery. The other 3 cases showed a good evolution with clinical remission of the symptoms. Pathological study of the explanted hearts confirmed the presence of the disease. CONCLUSIONS: ARVD is a serious cardiomyopathy that can develop malignant arrhythmias, severe ventricular dysfunction with right ventricular predominance, and sudden cardiac death. Orthotopic heart transplantation must always be considered in advanced cases of ARVD with malignant arrhythmias or refractory congestive heart failure with or without uncontrolled arrhythmias, because it is the only way to remit the symptoms and the disease.


Assuntos
Arritmias Cardíacas/etiologia , Arritmias Cardíacas/cirurgia , Transplante de Coração/métodos , Disfunção Ventricular Direita/cirurgia , Adolescente , Cardiomiopatias/etiologia , Cardiomiopatias/genética , Cardiomiopatias/cirurgia , Cromossomos Humanos , Eletrocardiografia , Feminino , Genes Dominantes , Transplante de Coração/mortalidade , Humanos , Masculino , Adulto Jovem
10.
Sci Rep ; 9(1): 16816, 2019 11 14.
Artigo em Inglês | MEDLINE | ID: mdl-31727935

RESUMO

The co-occurrence of domestic cats (Felis silvestris catus) and wild felids in rural landscapes can facilitate pathogen transmission. However, in the relatively-isolated regions of southern South America there have been no comprehensive studies to assess disease transmission risks between domestic cats and forest-dwelling wild felids such as guigna (Leopardus guigna). We evaluated hemoplasma infection and the possibility of transmission between domestic cats and guignas by comparing spatial and phylogenetic patterns of pathogen prevalence. Blood/spleen samples were collected from 102 wild guignas and 262 co-occurring rural domestic cats across the entire distribution range of guigna in Chile. Hemoplasma infection was assessed by direct sequencing of the 16S RNA gene. Infection with hemoplasmas was common and geographically widespread across different bioclimatic areas for both species. The most common feline Mycoplasma species in guigna and domestic cats were Candidatus M. haemominutum (CMhm) (15.7% guigna; 10.3% domestic cat) and Mycoplasma haemofelis (Mhf) (9.8% guigna, 6.1% domestic cat). A previously undescribed Mycoplasma sp. sequence was found in two guignas and one cat. Continuous forest-landscapes were associated with higher hemoplasma-prevalence in guignas. Shared hemoplasma nucleotide sequence types between guigna and domestic cats were rare, suggesting that cross-species transmission between guignas and domestic cats may occur, but is probably uncommon. Ectoparasites, which have been linked with hemoplasma transmission, were not found on guignas and were infrequent on domestic cats. Our results suggest that transmission pathways vary among hemoplasma species and, contrary to our predictions, domestic cats did not appear to be the main driver of hemoplasma infection in guignas in these human-dominated landscapes.


Assuntos
Doenças do Gato/microbiologia , Infecções por Mycoplasma/transmissão , Mycoplasma/classificação , Análise de Sequência de DNA/métodos , Animais , Animais Domésticos/microbiologia , Animais Selvagens/microbiologia , Doenças do Gato/transmissão , Gatos , Chile , DNA Bacteriano/genética , Felidae , Feminino , Masculino , Mycoplasma/genética , Mycoplasma/isolamento & purificação , Infecções por Mycoplasma/microbiologia , Filogenia , RNA Ribossômico 16S/genética , Especificidade da Espécie
11.
Minerva Endocrinol ; 32(4): 275-95, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18091664

RESUMO

Osteoporosis and fractures associated with it constitute a real and serious socio-medical problem, which only recently has come to the forefront of social consciousness. The authors are carrying out a critical re-examination of the medical literature of osteoporosis pharmacological treatment. Particular attention has been paid to studies which show a clear reduction of the primary endpoint that, in the case of this pathology, consists of a reduction of the fracturing event. According to the examination of the clinical studies introduced, antiresorptive bone agents, such as alendronate and risenderonate, turn out to be molecules with higher levels of evidence implicated on the reduction of the main osteoporotic fractures, in particular the reduction of vertebral and femoral fractures. The 10 years long-term extension studies, in particular those that have seen the employment of alendronate, found a positive outcome regarding densitometry data and a favorable trend in antifracture effectiveness. Ibandronate is another amino-bisphosphonate which was recently validated as an effective drug for the treatment of osteoporosis with its documented ability to meaningfully reduce vertebral fractures. Also ranelate of strontium, a drug that seems to explain its own result in a different way from the other antiresorptive bone agents, constitutes another valid alternative in the treatment of this pathology. Both of these molecules however, need further studies in order to estimate their antifracture effectiveness in the long term, particularly those related to femoral fractures. Teriparatide and the entire molecule paratohormone are usually not prescribed for its high cost in treatment and because, typically, patients with high-risk level fractures that are already affected, produce more vertebral fractures from moderate to severe intensity.


Assuntos
Conservadores da Densidade Óssea/uso terapêutico , Fraturas Ósseas/etiologia , Fraturas Ósseas/prevenção & controle , Osteoporose Pós-Menopausa/complicações , Alendronato/uso terapêutico , Reabsorção Óssea/prevenção & controle , Calcitonina/uso terapêutico , Ácido Clodrônico/uso terapêutico , Difosfonatos/uso terapêutico , Ácido Etidrônico/análogos & derivados , Ácido Etidrônico/uso terapêutico , Medicina Baseada em Evidências , Feminino , Humanos , Ácido Ibandrônico , Compostos Organometálicos/uso terapêutico , Ácido Risedrônico , Moduladores Seletivos de Receptor Estrogênico/uso terapêutico , Teriparatida/uso terapêutico , Tiofenos/uso terapêutico , Vitamina D/uso terapêutico
12.
Circ Res ; 88(7): 740-5, 2001 Apr 13.
Artigo em Inglês | MEDLINE | ID: mdl-11304498

RESUMO

Variant 3 of the congenital long-QT syndrome (LQTS-3) is caused by mutations in the gene encoding the alpha subunit of the cardiac Na(+) channel. In the present study, we report a novel LQTS-3 mutation, E1295K (EK), and describe its functional consequences when expressed in HEK293 cells. The clinical phenotype of the proband indicated QT interval prolongation in the absence of T-wave morphological abnormalities and a steep QT/R-R relationship, consistent with an LQTS-3 lesion. However, biophysical analysis of mutant channels indicates that the EK mutation changes channel activity in a manner that is distinct from previously investigated LQTS-3 mutations. The EK mutation causes significant positive shifts in the half-maximal voltage (V(1/2)) of steady-state inactivation and activation (+5.2 and +3.4 mV, respectively). These gating changes shift the window of voltages over which Na(+) channels do not completely inactivate without altering the magnitude of these currents. The change in voltage dependence of window currents suggests that this alteration in the voltage dependence of Na(+) channel gating may cause marked changes in action potential duration because of the unique voltage-dependent rectifying properties of cardiac K(+) channels that underlie the plateau and terminal repolarization phases of the action potential. Na(+) channel window current is likely to have a greater effect on net membrane current at more positive potentials (EK channels) where total K(+) channel conductance is low than at more negative potentials (wild-type channels), where total K(+) channel conductance is high. These findings suggest a fundamentally distinct mechanism of arrhythmogenesis for congenital LQTS-3.


Assuntos
Arritmias Cardíacas/diagnóstico , Coração/fisiopatologia , Síndrome do QT Longo/diagnóstico , Síndrome do QT Longo/genética , Canais de Sódio/genética , Adolescente , Substituição de Aminoácidos , Arritmias Cardíacas/genética , Linhagem Celular , Sequência Conservada , Análise Mutacional de DNA , Eletrocardiografia , Humanos , Ativação do Canal Iônico/efeitos dos fármacos , Ativação do Canal Iônico/genética , Rim/citologia , Rim/efeitos dos fármacos , Rim/metabolismo , Síndrome do QT Longo/fisiopatologia , Masculino , Mutação , Canal de Sódio Disparado por Voltagem NAV1.5 , Técnicas de Patch-Clamp , Fenótipo , Sódio/metabolismo , Canais de Sódio/metabolismo , Tetrodotoxina/farmacologia , Transfecção
14.
Handb Exp Pharmacol ; (171): 267-86, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16610348

RESUMO

The integration between molecular biology and clinical practice requires the achievement of fundamental steps to link basic science to diagnosis and management of patients. In the last decade, the study of genetic bases of human diseases has achieved several milestones, and it is now possible to apply the knowledge that stems from the identification of the genetic substrate of diseases to clinical practice. The first step along the process of linking molecular biology to clinical medicine is the identification of the genetic bases of inherited diseases. After this important goal is achieved, it becomes possible to extend research to understand the functional impairments of mutant protein(s) and to link them to clinical manifestations (genotype-phenotype correlation). In genetically heterogeneous diseases, it may be possible to identify locus-specific risk stratification and management algorithms. Finally, the most ambitious step in the study of genetic disease is to discover a novel pharmacological therapy targeted at correcting the inborn defect (locus-specific therapy) or even to "cure" the DNA abnormality by replacing the defective gene with gene therapy. At present, this curative goal has been successful only for very few diseases. In the field of inherited arrhythmogenic diseases, several genes have been discovered, and genetics is now emerging as a source of information contributing not only to a better diagnosis but also to risk stratification and management of patients. The functional characterization of mutant proteins has opened new perspectives about the possibility of performing gene-specific or mutation-specific therapy. In this chapter, we will briefly summarize the genetic bases of inherited arrhythmogenic conditions and we will point out how the information derived from molecular genetics has influenced the "optimal use of traditional therapies" and has paved the way to the development of gene-specific therapy.


Assuntos
Arritmias Cardíacas/tratamento farmacológico , Arritmias Cardíacas/genética , Síndrome do QT Longo/tratamento farmacológico , Animais , Desfibriladores Implantáveis , Canal de Potássio ERG1 , Canais de Potássio Éter-A-Go-Go/genética , Humanos , Síndrome do QT Longo/genética , Potenciais da Membrana/efeitos dos fármacos , Mutação , Canal de Sódio Disparado por Voltagem NAV1.5 , Canal de Liberação de Cálcio do Receptor de Rianodina/efeitos dos fármacos , Canal de Liberação de Cálcio do Receptor de Rianodina/genética , Canais de Sódio/genética , Taquicardia/tratamento farmacológico , Taquicardia/genética
15.
Circulation ; 102(9): 945-7, 2000 Aug 29.
Artigo em Inglês | MEDLINE | ID: mdl-10961955

RESUMO

BACKGROUND: Defects of the SCN5A gene encoding the cardiac sodium channel are associated with both the LQT3 subtype of long-QT syndrome and Brugada syndrome (BS). The typical manifestations of long-QT syndrome (QT interval prolongation) and BS (ST segment elevation in leads V1 through V3) may coexist in the same patients, which raises questions about the actual differences between LQT3 and BS. Intravenous flecainide is the standard provocative test used to unmask BS in individuals with concealed forms of the disease, and oral flecainide has been proposed as a treatment option for LQT3 patients because it may shorten their QT interval. METHODS AND RESULTS: We tested the possibility that in some LQT3 patients, flecainide might not only shorten the QT interval, but also produce an elevation of the ST segment. A total of 13 patients from 7 LQT3 families received intravenous flecainide using the protocol used for BS. As expected, QT, QTc, JT, and JTc interval shortening was observed in 12 of the 13 patients, and concomitant ST segment elevation in leads V1 through V3 (>/=2 mm) was observed in 6 of the 13. CONCLUSIONS: The data demonstrate that flecainide may induce ST segment elevation in LQT3 patients, raising concerns about the safety of flecainide therapy and demonstrating the existence of an intriguing overlap between LQT3 and BS.


Assuntos
Antiarrítmicos/uso terapêutico , Eletrocardiografia/efeitos dos fármacos , Flecainida/uso terapêutico , Síndrome do QT Longo/tratamento farmacológico , Mutação , Bloqueadores dos Canais de Sódio , Administração Oral , Adolescente , Adulto , Contraindicações , Diagnóstico Diferencial , Feminino , Humanos , Injeções Intravenosas , Síndrome do QT Longo/genética , Síndrome do QT Longo/fisiopatologia , Masculino , Fenótipo , Canais de Sódio/genética
16.
Circulation ; 102(20): 2509-15, 2000 Nov 14.
Artigo em Inglês | MEDLINE | ID: mdl-11076825

RESUMO

BACKGROUND: The ECG pattern of right bundle branch block and ST-segment elevation in leads V(1) to V(3) (Brugada syndrome) is associated with high risk of sudden death in patients with a normal heart. Current management and prognosis are based on a single study suggesting a high mortality risk within 3 years for symptomatic and asymptomatic patients alike. As a consequence, aggressive management (implantable cardioverter defibrillator) is recommended for both groups. METHODS AND RESULTS: Sixty patients (45 males aged 40+/-15 years) with the typical ECG pattern were clinically evaluated. Events at follow-up were analyzed for patients with at least one episode of aborted sudden death or syncope of unknown origin before recognition of the syndrome (30 symptomatic patients) and for patients without previous history of events (30 asymptomatic patients). Prevalence of mutations of the cardiac sodium channel was 15%, demonstrating genetic heterogeneity. During a mean follow-up of 33+/-38 months, ventricular fibrillation occurred in 5 (16%) of 30 symptomatic patients and in none of the 30 asymptomatic patients. Programmed electrical stimulation was of limited value in identifying patients at risk (positive predictive value 50%, negative predictive value 46%). Pharmacological challenge with sodium channel blockers was unable to unmask most silent gene carriers (positive predictive value 35%). CONCLUSIONS: At variance with current views, asymptomatic patients are at lower risk for sudden death. Programmed electrical stimulation identifies only a fraction of individuals at risk, and sodium channel blockade fails to unmask most silent gene carriers. This novel evidence mandates a reappraisal of therapeutic management.


Assuntos
Bloqueio de Ramo/diagnóstico , Bloqueio de Ramo/genética , Eletrocardiografia , Adulto , Substituição de Aminoácidos , Bloqueio de Ramo/terapia , Estudos de Coortes , Análise Mutacional de DNA , Morte Súbita Cardíaca/etiologia , Desfibriladores Implantáveis , Intervalo Livre de Doença , Terapia por Estimulação Elétrica , Eletrocardiografia/efeitos dos fármacos , Eletrocardiografia Ambulatorial , Feminino , Seguimentos , Humanos , Masculino , Canal de Sódio Disparado por Voltagem NAV1.5 , Penetrância , Valor Preditivo dos Testes , Reprodutibilidade dos Testes , Medição de Risco , Bloqueadores dos Canais de Sódio , Canais de Sódio/genética , Estatísticas não Paramétricas , Síncope/etiologia , Síndrome
17.
Circulation ; 101(6): 616-23, 2000 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-10673253

RESUMO

BACKGROUND: beta-blockers are routinely prescribed in congenital long-QT syndrome (LQTS), but the effectiveness and limitations of beta-blockers in this disorder have not been evaluated. METHODS AND RESULTS: The study population comprised 869 LQTS patients treated with beta-blockers. Effectiveness of beta-blockers was analyzed during matched periods before and after starting beta-blocker therapy, and by survivorship methods to determine factors associated with cardiac events while on prescribed beta-blockers. After initiation of beta-blockers, there was a significant (P<0.001) reduction in the rate of cardiac events in probands (0.97+/-1.42 to 0.31+/-0.86 events per year) and in affected family members (0. 26+/-0.84 to 0.15+/-0.69 events per year) during 5-year matched periods. On-therapy survivorship analyses revealed that patients with cardiac symptoms before beta-blockers (n=598) had a hazard ratio of 5.8 (95% CI, 3.7 to 9.1) for recurrent cardiac events (syncope, aborted cardiac arrest, or death) during beta-blocker therapy compared with asymptomatic patients; 32% of these symptomatic patients will have another cardiac event within 5 years while on prescribed beta-blockers. Patients with a history of aborted cardiac arrest before starting beta-blockers (n=113) had a hazard ratio of 12.9 (95% CI, 4.7 to 35.5) for aborted cardiac arrest or death while on prescribed beta-blockers compared with asymptomatic patients; 14% of these patients will have another arrest (aborted or fatal) within 5 years on beta-blockers. CONCLUSIONS: beta-blockers are associated with a significant reduction in cardiac events in LQTS patients. However, syncope, aborted cardiac arrest, and LQTS-related death continue to occur while patients are on prescribed beta-blockers, particularly in those who were symptomatic before starting this therapy.


Assuntos
Antagonistas Adrenérgicos beta/administração & dosagem , Síndrome do QT Longo/tratamento farmacológico , Adolescente , Antagonistas Adrenérgicos beta/efeitos adversos , Adulto , Atenolol/administração & dosagem , Atenolol/efeitos adversos , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Síndrome do QT Longo/congênito , Síndrome do QT Longo/fisiopatologia , Masculino , Metoprolol/administração & dosagem , Metoprolol/efeitos adversos , Nadolol/administração & dosagem , Nadolol/efeitos adversos , Propranolol/administração & dosagem , Propranolol/efeitos adversos , Análise de Sobrevida
18.
Circulation ; 104(5): 557-62, 2001 Jul 31.
Artigo em Inglês | MEDLINE | ID: mdl-11479253

RESUMO

BACKGROUND: Whenever a proband is identified with long-QT syndrome (LQTS), his or her parents and siblings should be evaluated regarding the possibility of carrying the disorder. In the majority of cases, one of the proband's parents and one or more siblings are affected. The aim of this study was (1) to determine whether the clinical severity of LQTS in the proband is useful in identifying first-degree family members at high risk for cardiac events, and (2) to evaluate the clinical course of affected parents and siblings of LQTS probands. METHODS AND RESULTS: The clinical and ECG characteristics of 211 LQTS probands and 791 first-degree relatives (422 parents and 369 siblings) were studied to determine if the clinical profile of the proband is useful in determining the clinical severity of LQTS in affected parents and siblings. Affected female parents of an LQTS proband had a greater cumulative risk for a first cardiac event than affected male parents. The probability of a parent or sibling having a first cardiac event was not significantly influenced by the severity of the proband's clinical symptoms. Female sex and QT(c) duration were risk factors for cardiac events among affected parents, and QT(c) was the only risk factor for cardiac events in affected siblings. CONCLUSIONS: The severity profile of LQTS in a proband was not found to be useful in identifying the clinical severity of LQTS in affected first-degree relatives of the proband.


Assuntos
Síndrome do QT Longo/fisiopatologia , Adolescente , Adulto , Idade de Início , Doenças Cardiovasculares/genética , Doenças Cardiovasculares/fisiopatologia , Criança , Eletrocardiografia , Família , Saúde da Família , Feminino , Humanos , Síndrome do QT Longo/genética , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Estatística como Assunto
19.
Circulation ; 102(23): 2849-55, 2000 Dec 05.
Artigo em Inglês | MEDLINE | ID: mdl-11104743

RESUMO

BACKGROUND: Congenital long-QT syndrome (LQTS) is caused by mutations of genes encoding the slow component of the delayed rectifier current (LQT1, LQT5), the rapid component of the delayed rectifier current (LQT2, LQT6), or the Na(+) current (LQT3), resulting in ST-T-wave abnormalities on the ECG. This study evaluated the spectrum of ST-T-wave patterns and repolarization parameters by genotype and determined whether genotype could be identified by ECG. METHODS AND RESULTS: ECGs of 284 gene carriers were studied to determine ST-T-wave patterns, and repolarization parameters were quantified. Genotypes were identified by individual ECG versus family-grouped ECG analysis in separate studies using ECGs of 146 gene carriers from 29 families and 233 members of 127 families undergoing molecular genotyping, respectively. Ten typical ST-T patterns (4 LQT1, 4 LQT2, and 2 LQT3) were present in 88% of LQT1 and LQT2 carriers and in 65% of LQT3 carriers. Repolarization parameters also differed by genotype. A combination of quantified repolarization parameters identified genotype with sensitivity/specificity of 85%/70% for LQT1, 83%/94% for LQT2, and 47%/63% for LQT3. Typical patterns in family-grouped ECGs best identified the genotype, being correct in 56 of 56 (21 LQT1, 33 LQT2, and 2 LQT3) families with mutation results. CONCLUSIONS: Typical ST-T-wave patterns are present in the majority of genotyped LQTS patients and can be used to identify LQT1, LQT2, and possibly LQT3 genotypes. Family-grouped ECG analysis improves genotype identification accuracy. This approach can simplify genetic screening by targeting the gene for initial study. The multiple ST-T patterns in each genotype raise questions regarding the pathophysiology and regulation of repolarization in LQTS.


Assuntos
Eletroencefalografia/estatística & dados numéricos , Síndrome do QT Longo/congênito , Síndrome do QT Longo/diagnóstico , Adolescente , Adulto , Biomarcadores , Criança , Pré-Escolar , Mapeamento Cromossômico/estatística & dados numéricos , Diagnóstico Diferencial , Feminino , Expressão Gênica , Genótipo , Humanos , Síndrome do QT Longo/genética , Masculino , Fenótipo , Sensibilidade e Especificidade
20.
Circulation ; 103(1): 89-95, 2001 Jan 02.
Artigo em Inglês | MEDLINE | ID: mdl-11136691

RESUMO

BACKGROUND: The congenital long-QT syndrome (LQTS) is caused by mutations on several genes, all of which encode cardiac ion channels. The progressive understanding of the electrophysiological consequences of these mutations opens unforeseen possibilities for genotype-phenotype correlation studies. Preliminary observations suggested that the conditions ("triggers") associated with cardiac events may in large part be gene specific. METHODS AND RESULTS: We identified 670 LQTS patients of known genotype (LQT1, n=371; LQT2, n=234; LQT3, n=65) who had symptoms (syncope, cardiac arrest, sudden death) and examined whether 3 specific triggers (exercise, emotion, and sleep/rest without arousal) differed according to genotype. LQT1 patients experienced the majority of their events (62%) during exercise, and only 3% occurred during rest/sleep. These percentages were almost reversed among LQT2 and LQT3 patients, who were less likely to have events during exercise (13%) and more likely to have events during rest/sleep (29% and 39%). Lethal and nonlethal events followed the same pattern. Corrected QT interval did not differ among LQT1, LQT2, and LQT3 patients (498, 497, and 506 ms, respectively). The percent of patients who were free of recurrence with ss-blocker therapy was higher and the death rate was lower among LQT1 patients (81% and 4%, respectively) than among LQT2 (59% and 4%, respectively) and LQT3 (50% and 17%, respectively) patients. CONCLUSIONS: Life-threatening arrhythmias in LQTS patients tend to occur under specific circumstances in a gene-specific manner. These data allow new insights into the mechanisms that relate the electrophysiological consequences of mutations on specific genes to clinical manifestations and offer the possibility of complementing traditional therapy with gene-specific approaches.


Assuntos
Síndrome do QT Longo/genética , Antagonistas Adrenérgicos beta/uso terapêutico , Adulto , Arritmias Cardíacas/etiologia , Arritmias Cardíacas/genética , Arritmias Cardíacas/fisiopatologia , Morte Súbita Cardíaca/etiologia , Eletrocardiografia , Emoções , Exercício Físico , Feminino , Genótipo , Humanos , Canais Iônicos/genética , Síndrome do QT Longo/classificação , Síndrome do QT Longo/diagnóstico , Síndrome do QT Longo/tratamento farmacológico , Síndrome do QT Longo/fisiopatologia , Masculino , Fenótipo , Fatores Sexuais , Sono , Taxa de Sobrevida , Síncope/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA